Immune checkpoint mediated by PD-1 and its ligand PD-L1 has been approved to be used for human cancer treatment, and it has been revealed that SPOP deletion could block the ubiquitin-induced PD-L1 degradation to increase PD-L1 protein expression [28]. Here, CD274 is linked to cancer.